tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline
PremiumRatingsCautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline
1M ago
Prime Medicine’s Promising Advances in Gene Editing Justify Buy Rating
Premium
Ratings
Prime Medicine’s Promising Advances in Gene Editing Justify Buy Rating
2M ago
Prime Medicine price target lowered to $4.25 from $5 at Citi
Premium
The Fly
Prime Medicine price target lowered to $4.25 from $5 at Citi
2M ago
Intellia Therapeutics price target lowered to $9 from $14 at Wedbush
PremiumThe FlyIntellia Therapeutics price target lowered to $9 from $14 at Wedbush
2M ago
Prime Medicine price target raised to $5 from $4 at Citi
Premium
The Fly
Prime Medicine price target raised to $5 from $4 at Citi
2M ago
PRME Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
PRME Earnings this Week: How Will it Perform?
2M ago
Prime Medicine Unveils New Prime Editing Advancements
PremiumCompany AnnouncementsPrime Medicine Unveils New Prime Editing Advancements
4M ago
Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position
Premium
Ratings
Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position
5M ago
Prime Medicine Reports Q2 2025 Results and Strategic Updates
Premium
Company Announcements
Prime Medicine Reports Q2 2025 Results and Strategic Updates
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100